2019 Life Sciences Industry Report from CLSA Shows Strong Growth in Jobs, Investments and Therapeutic Pipeline in California
CLSA and PwC US today released the 2019 California Life Sciences Industry Report, which shows that California’s life sciences sector directly employed 311,226 people, generated $178 billion in revenue, is projected to attract $7.6 billion in venture capital (VC) and received $3.9 billion in funding from the NIH.
Trump Administration Advancing Proposals Outlined in “Blueprint” to Address Prescription Drug Pricing
Addressing drug pricing and improving healthcare access and affordability remains a salient topic on Capitol Hill, in the Trump Administration, with industry and the public. Over the summer, the Administration released its American Patients First blueprint, and over the past several weeks, the Administration has announced draft or final proposals intended to lower drug prices and increase access to affordable prescription drugs.
Governor Brown Signs SB 212 to Establish a Statewide Drugs & Sharps Take-Back Program
On the final day for signing or vetoing bills, California Gov. Jerry Brown signed into law SB 212 (Jackson), which establishes a comprehensive statewide take-back system for sharps and medications.
What’s Next for the Remainder of 2018? Federal Legislative Outlook on Government Funding, Medical Device Tax and PAHPA Reauthorization
Both the House and Senate have adjourned until after the midterm elections. While the outcome of the elections will determine whether the Democrats win a majority in either the House or the Senate (or both), or if the Republicans maintain control of one or both chambers in the 116th Congress, both the House and Senate will return to Washington, D.C. in late November and early December (approximately 16-20 legislative days) to finish legislative work prior to the end of the year and the 115th Congress.
Possible new Life Sciences Hub in Los Angeles
California Life Sciences Association (CLSA) welcomes the Los Angeles World Airports (LAWA) vision to begin the RFQ/RFP process for the development of a biomedical complex on the LAWA northside area site. This concept will greatly bolster California’s ability to keep up with the needs of the sector and further provide economic development opportunities for innovative life science companies.
CLSA in MD+DI: What Could the Midterm Elections Mean for Medtech?
CLSA’s VP of Federal Government Relations Jenny Carey was recently featured in MD+DI commenting on life sciences priorities leading into the 2018 midterm elections
CLSA in BioSpace: CLSA Names Pantheon DiNA Award Winners
CLSA’s 2018 Pantheon DiNA Awards are coming up 11/30. Learn about the individuals & companies being honored in this BioSpace article.
CLSA Applauds Governor Brown for Signing SB 212, Legislation to Establish a Statewide Drugs and Sharps Take-Back Program
Today, CLSA applauded Gov. Jerry Brown for signing Senate Bill 212, legislation to establish a statewide drugs and sharps take-back program. SB 212 was approved by the California Legislature earlier this year and signed Sept. 30, by Brown.
CLSA in Politico: California Governor approves new law to protect clinical trials, research
CLSA was recently featured in Politico applauding Gov. Jerry Brown on signing SB 1121 into law, to protect clinical trials and patient research in California.
With Sacramento Legislative Session Over, CLSA Looking Forward to Final Few Days for Governor’s Actions
Two major bills of interest to CLSA have been presented to Governor Brown for his signing or veto: SB 1121 (Dodd), which was signed this week, and SB 212 (Jackson), on which we await action by the Governor. A third key bill of interest to CLSA, AB 2167 (Chau), died in the Senate during the final week of the legislative session.